Abstract

Research Article

Misoprostol Usage in the Kingdom of Bahrain: A Retrospective Study

Maryam Alsalem*, Hosni Malas, Gulmeen Raza and Rehab Ismael

Published: 07 November, 2025 | Volume 8 - Issue 4 | Pages: 092-095

Introduction: The document introduces the topic of medical termination of pregnancy (MTP) using misoprostol, a synthetic prostaglandin E1 analogue. It discusses the advantages and challenges of this method, and the research gap in the Gulf region and the Middle East. It also states the aim of the study, which is to evaluate the safety, efficacy, and acceptability of misoprostol for MTP in Bahrain. 
Methods: The document describes the study design, data source, and inclusion criteria. It explains that the data was collected from the Hope system in King Hamad University Hospital and included women in the first and second trimester of pregnancy who were undergoing MTP as per the FIGO protocol. It also mentions the statistical analysis that was used to compare the outcomes of different regimens, dosages, and routes of administration of misoprostol. 
Results: The document reports the main findings of the study, such as the success and failure rates of MTP, the association between previous deliveries and MTP outcomes, the optimal number and route of misoprostol doses, the length of hospital stay, and the incidence of complications. It also presents some figures to illustrate the results. 
Discussion: The document interprets the results and compares them with previous studies. It highlights the high efficacy of the sublingual route of misoprostol but also acknowledges the side effects and limitations of this route. It suggests that two doses of 600mcg or 800mcg of misoprostol are sufficient for MTP. It also identifies the strengths and weaknesses of the study and proposes some future directions for research. 
Conclusion: The document concludes that the study provides a better understanding of the outcomes of misoprostol for MTP in a controlled environment. It asserts that misoprostol is a safe and effective option for women seeking abortion in the first and second trimester, especially in low-resource settings. It also emphasizes the need for evidence-based guidelines and counseling for misoprostol use.

Read Full Article HTML DOI: 10.29328/journal.cjog.1001196 Cite this Article Read Full Article PDF

References

  1. Jayaweera R, Egwuatu I, Nmezi S, Kristianingrum IA, Zurbriggen R, Grosso B, et al. Medication abortion safety and effectiveness with misoprostol alone. JAMA Netw Open. 2023;6(10):e2340042. Available from: https://doi.org/10.1001/jamanetworkopen.2023.40042
  2. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology, Society of Family Planning. Medication abortion up to 70 days of gestation: ACOG practice bulletin, number 225. Obstet Gynecol. 2020;136(4):e31-e47. Available from: https://doi.org/10.1097/aog.0000000000004082
  3. Raymond EG, Grossman D, Mark A, Upadhyay UD, Dean G, Creinin MD, et al. Commentary: No-test medication abortion: a sample protocol for increasing access during a pandemic and beyond. Contraception. 2020;101:361–6. Available from: https://doi.org/10.1016/j.contraception.2020.04.005
  4. Alsibiani SA. Use of misoprostol for self-induced medical abortions among Saudi women: a call for attention. Gynecol Obstet Invest. 2014;78(2):88-93. Available from: https://doi.org/10.1159/000363238
  5. Morris JL, Winikoff B, Dabash R, Weeks A, Faundes A, Gemzell-Danielsson K, et al. FIGO's updated recommendations for misoprostol used alone in gynecology and obstetrics. Int J Gynecol Obstet. 2017;138:363-366. Available from: https://doi.org/10.1002/ijgo.12181
  6. Wu HL, Marwah S, Wang P, Wang QM, Chen XW. Misoprostol for medical treatment of missed abortion: a systematic review and network meta-analysis. Sci Rep. 2017;7:1664. Available from: https://doi.org/10.1038/s41598-017-01892-0
  7. Khan UI, Iftikhar B, Jabeen SS, Akram NA, Subktageen B, Fatima A. Comparison of the sublingual and vaginal misoprostol for medical termination of pregnancy in cases of first and second trimester abortion: a quasi-experimental study. Pak Armed Forces Med J. 2022;72(2):414-418. Available from: https://www.pafmj.org/PAFMJ/article/view/7241
  8. Hamoda H, Ashok PW, Flett GM, Templeton A. A randomized controlled comparison of sublingual and vaginal administration of misoprostol for cervical priming before first-trimester surgical abortion. Am J Obstet Gynecol. 2004;190:55–59. Available from: https://doi.org/10.1016/j.ajog.2003.08.025
  9. Turner JV, Agatonovic-Kustrn S, Ward H. Off-label use of misoprostol in gynaecology. Facts Views Vis Obgyn. 2015;7(4):261-264. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058416/
  10. Raymond EG, Harrison M, Weaver MA. Efficacy of misoprostol alone for first-trimester medical abortion. Natl Libr Med. 2019. Available from: https://doi.org/10.1097/AOG.0000000000003017

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Figure 1

Figure 5

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?